• Personal or family history of Medullary Thyroid Cancer or in patients with multiple endocrine neoplasia syndrome type 2

• Known hypersensitivity to GLP-1, GIP or to any of the product components

• If you are pregnant or plan to become pregnant within the next 2 months or are currently breastfeeding, we do not offer GLP-1/GIP therapy per our established protocols

BMI less than 27 will disqualify you from receiving GLP-1/GIP therapy from Hydrations Wellness per our established protocols.

Clients new to GLP-1/GIP injections will need to complete some intake forms prior to beginning their first injection.  A Medical review will be completed within 1-2 business days and you will be notified of your eligibility.  You may complete these forms online by CLICKING HERE

Upon Approval, you will be required to pay $250/month at the beginning of week 1, week 5, week 9 and week 13 injections.  If you discontinue use, no refunds will be able to be given for the month in which you prepaid after the first injection for that month has been given.

MAINTENANCE/EXISTING USERS

Once you complete your 20 week protocol, you will be able to pay for your maintenance dose injections at time of service.  If you are an existing user who started GLP-1/GIP therapy prior to visiting Hydrations Wellness, you will need to complete the eligibility form referenced above and include the date and dose of your last injection so we can continue your therapy.

• Based on findings in rats and mice, GLP-1/GIP therpay may cause thyroid C-cell tumors, including MTC, in humans as human relevance of GLP-1-induced rodent thyroid C-cell tumors has not been determined

</ br>

• In control trials, acute pancreatitis was reported (0.3 events [SC] per 100 patient years);  After initiating treatment, monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting);  If pancreatitis is suspected, discontinue GLP-1/GIP Therapy and do not restart if confirmed

</ br>

• Patients treated with GLP-1/GIP Therapy showed an increased risk of diabetic retinopathy complications compared with placebo/comparator; rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy

</ br>

• Post-marketing reports describe acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis in patients treated with GLP-1/GIP receptor agonists; a majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration; We may require bloodwork to monitor renal function when initiating or escalating doses of GLP-1/GIP Therapy in patients reporting adverse GI reactions

</ br>
</ br>

• Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported with GLP-1/GIP receptor agonists; if hypersensitivity reactions occur, discontinue treatment, treat promptly, and monitor until signs and symptoms resolve

• nausea,
• vomiting,
• stomach pain,
• loss of appetite,
• diarrhea, and/or constipation

If you experience these side effects, and they are more than tolerable, we will lower your dosage to the last dose tolerated without side effects.

Serious/Rare side effects of GLP-1 therapy include:

• hives,
• itching,
• dizziness,
• fast heartbeats,
• difficult breathing,
• swelling of the face, lips, tongue, or throat,
• vision changes,
• swelling or a lump in the neck,
• trouble swallowing,
• hoarse voice,
• shortness of breath,
• severe pain in your upper stomach spreading to the back,
• weakness,
• sweating,
• confusion,
• irritability,
• feeling jittery,
• little or no urination,
• swelling in the feet or ankles, and
• tiredness

If you experience these side effects, you may need to seek immediate medical attention.  You will no longer be eligible for future injections.

Gliclazide, glipizide, glibenclamide, glimepiride, nateglinide and repaglinide.

These drugs are more likely to cause hypoglycemic events in diabetics who use GLP-1/GIP for weight loss.

Precautions should be taken when using non-prescription medications as well.  Per Mayo Clininc, the medications include:

OTC medicines for: appetite control, asthma, colds, cough, hay fever, or sinus problems.